Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
News|Articles|October 27, 2026
Stress and Mood Ingredients in 2026: New Data, New Entrants, and Regulatory Signals
Author(s)Erin McEvoy
A roundup of recent adaptogen trials, newer botanical and fermentation-derived ingredients, and approvals in Canada and South Korea, with a look at the limits of the evidence for manufacturers.
Advertisement
Advertisement
Stress and mood remain among the most active areas of botanical innovation, with recent coverage pointing to new clinical data on established adaptogens, regulatory recognition abroad, and newer ingredients entering the field. This roundup summarizes stress- and mood-related findings from Nutritional Outlook’s coverage since the start of 2026, with a focus on what they mean for supplement manufacturers.
Related to this article
Formulators are moving toward botanicals like ashwagandha, bacopa, saffron, and PEA that target the stress, cortisol, and nervous-system pathways behind restless nights.
TriNutra is presenting new data on its standardized black seed oil ingredient at SupplySide Global, adding to a growing body of research on how gut bacteria and the body's stress response may influence each other.
From skin and coat to oral health, a roundup of recent pet supplement research, regulatory signals, and product developments.
AHPA, CHPA, CRN, and UNPA say placing ODS under the Office of Nutrition Research would add a layer of bureaucracy. NIH is accepting comments through October 28.
From canine arthritis to the microbiome, and from the proposed Animal Health Supplement Act to owners’ views on longevity, here is what has been developing for companion animal products.
Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
Advertisement
Advertisement